Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
1(14%)
Results Posted
100%(5 trials)

Phase Distribution

Ph phase_3
3
43%
Ph phase_2
2
29%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(2)
Completed(5)

Detailed Status

Completed5
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 22 (28.6%)
Phase 33 (42.9%)

Trials by Status

active_not_recruiting114%
not_yet_recruiting114%
completed571%

Recent Activity

1 active trials
Showing 5 of 7
completedphase_3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

NCT05526716
completedphase_2

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

NCT05596734
not_yet_recruitingphase_3

Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

NCT06800950
active_not_recruitingphase_1

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

NCT06622590
completedphase_2

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

NCT05886777
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05526716Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)

Completed
NCT05596734Phase 2

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

Completed
NCT06800950Phase 3

Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Not Yet Recruiting
NCT06622590Phase 1

Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Active Not Recruiting
NCT05886777Phase 2

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Completed
NCT03615482Phase 3

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

Completed
NCT05052697Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7